Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 1;35(8):1313-1317.
doi: 10.1097/QAD.0000000000002863.

Advancing long-acting and extended delivery HIV prevention and treatment regimens through behavioural science: NIH workshop directions

Tia Morton  1 , Wairimu Chege  1 , Edith Swann  1 , Theresa E Senn  2 , Naana Cleland  1 , Philip O Renzullo  1 , Michael J Stirratt  2
Affiliations

Advancing long-acting and extended delivery HIV prevention and treatment regimens through behavioural science: NIH workshop directions

Tia Morton et al. AIDS. .
No abstract available

PubMed Disclaimer

References

    1. US FDA. Press release: FDA approves first extended-release, injectable drug regimen for adults living with HIV [Internet]. Washington, DC: US FDA; 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-e... . [Accessed 23 January 2021].
    1. ViiV. Press release: ViiV Healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting, regimen for the treatment of HIV [Internet]. Middlesex: ViiV Healthcare; 2020. https://viivhealthcare.com/en-gb/media/press-releases/2020/march/viiv-he... . [Accessed 10 November 2020].
    1. NIH. Press release: vaginal ring for HIV prevention receives positive opinion from European regulator [Internet]. Bethesda: U.S. National Institutes of Health; 2020. https://www.nih.gov/news-events/news-releases/vaginal-ring-hiv-preventio... . [Accessed 10 November 2020].
    1. WHO. Press Release: WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection [Internet]. Geneva: WHO; 2021. https://www.who.int/news/item/26-01-2021-who-recommends-the-dapivirine-v... . [Accessed 27 January 2021].
    1. Landowitz RJ, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L, et al. HPTN 083 interim results: pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM, TGW) [Abstract OAXLB01]. Paper presented at 23rd International AIDS Conference, 6--10 July 2020; Internet.

MeSH terms

Substances